{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T22:54:14Z","timestamp":1767480854989,"version":"3.37.3"},"reference-count":92,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1151646"],"award-info":[{"award-number":["OPP1151646"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1017604"],"award-info":[{"award-number":["OPP1017604"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1032144"],"award-info":[{"award-number":["OPP1032144"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense (DOD)","award":["W81XWH-07-2-0067"],"award-info":[{"award-number":["W81XWH-07-2-0067"]}]},{"name":"Swiss National Science Foundation (SNSF)","award":["P3SMP3_148406\/1"],"award-info":[{"award-number":["P3SMP3_148406\/1"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0194266","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T17:46:47Z","timestamp":1524764807000},"page":"e0194266","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant"],"prefix":"10.1371","volume":"13","author":[{"given":"Yingxia","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8014-9291","authenticated-orcid":true,"given":"Hung V.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine E.","family":"Linton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Norais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeeAnn","family":"Martinez-Guzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yide","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Situ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selen","family":"Karaca-Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayali","family":"Onkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hilt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Padma","family":"Malyala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushit","family":"Lodaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillis","family":"Otten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukti","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"LaBranche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Montefiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Fulp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Zolla-Pazner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Xin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barton F.","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson L.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mangala","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan W.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"key":"ref1","unstructured":"UNAIDS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/THA_narrative_report_2015.pdf\" xlink:type=\"simple\">http:\/\/www.unaids.org\/sites\/default\/files\/country\/documents\/THA_narrative_report_2015.pdf<\/ext-link>."},{"key":"ref2","unstructured":"UNAIDS. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/aidsinfo.unaids.org\" xlink:type=\"simple\">http:\/\/aidsinfo.unaids.org<\/ext-link>."},{"key":"ref3","unstructured":"WHO. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/hiv\/topics\/vaccines\/Vaccines\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/hiv\/topics\/vaccines\/Vaccines\/en\/<\/ext-link>."},{"key":"ref4","doi-asserted-by":"crossref","first-page":"33971","DOI":"10.1038\/srep33971","article-title":"Multiple introductions and onward transmission of non-pandemic HIV-1 subtype B strains in North America and Europe","volume":"6","author":"M Cabello","year":"2016","journal-title":"Sci Rep"},{"issue":"11\u201312","key":"ref5","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/sj.cr.7290373","article-title":"Snapshot of HIV pathogenesis in China","volume":"15","author":"NK Saksena","year":"2005","journal-title":"Cell Res"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.virol.2010.03.048","article-title":"Explosive HIV-1 subtype B&apos; epidemics in Asia driven by geographic and risk group founder events","volume":"402","author":"Y Li","year":"2010","journal-title":"Virology"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nri1307","article-title":"Identifying epitopes of HIV-1 that induce protective antibodies","volume":"4","author":"S Zolla-Pazner","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev.immunol.24.021605.090557","article-title":"GP120: target for neutralizing HIV-1 antibodies","volume":"24","author":"R Pantophlet","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2174\/157016207782418533","article-title":"Broadening our view of protective antibody responses against HIV","volume":"5","author":"B Burke","year":"2007","journal-title":"Curr HIV Res"},{"issue":"18","key":"ref10","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1128\/JVI.00652-15","article-title":"An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates","volume":"89","author":"MC Wise","year":"2015","journal-title":"J Virol"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"e1005315","DOI":"10.1371\/journal.ppat.1005315","article-title":"Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control","volume":"12","author":"ME Ackerman","year":"2016","journal-title":"PLoS Pathog"},{"issue":"23","key":"ref12","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(12)70088-9","article-title":"Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B\/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144","volume":"12","author":"ML Robb","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/infdis\/jis478","article-title":"Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B\/E","volume":"207","author":"S Rerks-Ngarm","year":"2013","journal-title":"J Infect Dis"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"e53629","DOI":"10.1371\/journal.pone.0053629","article-title":"Analysis of V2 antibody responses induced in vaccinees in the ALVAC\/AIDSVAX HIV-1 vaccine efficacy trial","volume":"8","author":"S Zolla-Pazner","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"e87572","DOI":"10.1371\/journal.pone.0087572","article-title":"Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection","volume":"9","author":"S Zolla-Pazner","year":"2014","journal-title":"PLoS One"},{"issue":"7420","key":"ref18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2","volume":"490","author":"M Rolland","year":"2012","journal-title":"Nature"},{"issue":"9","key":"ref19","doi-asserted-by":"crossref","first-page":"e75665","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"R Gottardo","year":"2013","journal-title":"PLoS One"},{"issue":"228","key":"ref20","doi-asserted-by":"crossref","first-page":"228ra39","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"NL Yates","year":"2014","journal-title":"Sci Transl Med"},{"issue":"228","key":"ref21","doi-asserted-by":"crossref","first-page":"228ra38","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"AW Chung","year":"2014","journal-title":"Sci Transl Med"},{"issue":"8","key":"ref22","doi-asserted-by":"crossref","first-page":"e1005817","DOI":"10.1371\/journal.ppat.1005817","article-title":"Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses","volume":"12","author":"MZ Tay","year":"2016","journal-title":"PLoS Pathog"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology","volume":"163","author":"AW Chung","year":"2015","journal-title":"Cell"},{"key":"ref24","unstructured":"Enterprise GH. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/vaccineenterprise.org\/content\/P5Partnership\" xlink:type=\"simple\">http:\/\/vaccineenterprise.org\/content\/P5Partnership<\/ext-link>."},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"e0157391","DOI":"10.1371\/journal.pone.0157391","article-title":"Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa","volume":"11","author":"C Zambonelli","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"ref26","article-title":"Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions","volume":"4","author":"Z Wang","year":"2016","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nbt.3187","article-title":"COMPASS identifies T-cell subsets correlated with clinical outcomes","volume":"33","author":"L Lin","year":"2015","journal-title":"Nat Biotechnol"},{"key":"ref28","unstructured":"Tomaras G, editor PL01.02: Overview of Humoral and Cellular Immune Responses to HIV Vaccination. HIV Research for Prevention (HIVR4P) 2016; 2016; Chicago, USA."},{"key":"ref29","unstructured":"NIH_News. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/large-scale-hiv-vaccine-trial-launch-south-africa\" xlink:type=\"simple\">https:\/\/www.nih.gov\/news-events\/news-releases\/large-scale-hiv-vaccine-trial-launch-south-africa<\/ext-link>."},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1128\/JVI.68.12.8312-8320.1994","article-title":"Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1","volume":"68","author":"MK Gorny","year":"1994","journal-title":"J Virol"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1128\/JVI.00718-12","article-title":"Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion","volume":"87","author":"SM Alam","year":"2013","journal-title":"J Virol"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ebiom.2014.10.022","article-title":"Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses","volume":"1","author":"S Zolla-Pazner","year":"2014","journal-title":"EBioMedicine"},{"issue":"5","key":"ref33","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/infdis\/170.5.1288","article-title":"Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers","volume":"170","author":"JO Kahn","year":"1994","journal-title":"J Infect Dis"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1586\/14760584.2.2.197","article-title":"MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile","volume":"2","author":"A Podda","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"DT O'Hagan","year":"2007","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.1402604","article-title":"Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination","volume":"195","author":"G Lofano","year":"2015","journal-title":"J Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2016.02.010","article-title":"Approaches to preventative and therapeutic HIV vaccines","volume":"17","author":"GE Gray","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"19","key":"ref38","doi-asserted-by":"crossref","first-page":"9998","DOI":"10.1128\/JVI.05045-11","article-title":"Analysis of a clonal lineage of HIV-1 envelope V2\/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors","volume":"85","author":"M Bonsignori","year":"2011","journal-title":"J Virol"},{"issue":"45","key":"ref39","doi-asserted-by":"crossref","first-page":"18214","DOI":"10.1073\/pnas.1317855110","article-title":"Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors","volume":"110","author":"SM Alam","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref40","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/JVI.02297-12","article-title":"Antigenicity and immunogenicity of transmitted\/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1","volume":"87","author":"HX Liao","year":"2013","journal-title":"J Virol"},{"issue":"Suppl 3","key":"ref41","first-page":"S277","article-title":"Development of bivalent rgp120 vaccines to prevent HIV type 1 infection","volume":"14","author":"PW Berman","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pep.2008.02.002","article-title":"Inhibition of V3-specific cleavage of recombinant HIV-1 gp120 produced in Chinese hamster ovary cells","volume":"59","author":"SX Du","year":"2008","journal-title":"Protein Expr Purif"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.immuni.2012.11.011","article-title":"Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2","volume":"38","author":"HX Liao","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1128\/JVI.76.6.2835-2847.2002","article-title":"Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus","volume":"76","author":"IK Srivastava","year":"2002","journal-title":"J Virol"},{"issue":"11","key":"ref45","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1089\/aid.2015.0034","article-title":"IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1\/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I\/II Vaccine Trials Using Different Vaccine Regimens","volume":"31","author":"N Karasavvas","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"21","key":"ref46","doi-asserted-by":"crossref","first-page":"11502","DOI":"10.1128\/JVI.05363-11","article-title":"Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals","volume":"85","author":"GD Tomaras","year":"2011","journal-title":"J Virol"},{"issue":"16","key":"ref47","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1128\/JVI.03635-14","article-title":"Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates","volume":"89","author":"X Shen","year":"2015","journal-title":"J Virol"},{"issue":"16","key":"ref48","doi-asserted-by":"crossref","first-page":"10108","DOI":"10.1128\/JVI.79.16.10108-10125.2005","article-title":"Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies","volume":"79","author":"M Li","year":"2005","journal-title":"J Virol"},{"article-title":"Nonparametric Statistical Methods","year":"1999","author":"M Hollander","key":"ref49"},{"issue":"287","key":"ref50","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/01621459.1959.10501526","article-title":"Remarks on zeros and ties in the Wilcoxon signed rank procedures","volume":"54","author":"JW Pratt","year":"1959","journal-title":"Journal of the American Statistical Association"},{"issue":"8","key":"ref51","doi-asserted-by":"crossref","first-page":"e43903","DOI":"10.1371\/journal.pone.0043903","article-title":"Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials","volume":"7","author":"B Yu","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"ref52","doi-asserted-by":"crossref","first-page":"e1005456","DOI":"10.1371\/journal.ppat.1005456","article-title":"Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination","volume":"12","author":"AE Mahan","year":"2016","journal-title":"PLoS Pathog"},{"issue":"6133","key":"ref53","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.1233989","article-title":"Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization","volume":"340","author":"IS Georgiev","year":"2013","journal-title":"Science"},{"issue":"12","key":"ref54","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nchembio.1685","article-title":"Recent strategies targeting HIV glycans in vaccine design","volume":"10","author":"S Horiya","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/pr300870t","article-title":"Characterization of host-cell line specific glycosylation profiles of early transmitted\/founder HIV-1 gp120 envelope proteins","volume":"12","author":"EP Go","year":"2013","journal-title":"J Proteome Res"},{"issue":"4","key":"ref56","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1021\/pr7008252","article-title":"GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans","volume":"7","author":"A Ceroni","year":"2008","journal-title":"J Proteome Res"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1007\/s13361-012-0425-8","article-title":"MALDI-MS\/MS with traveling wave ion mobility for the structural analysis of N-linked glycans","volume":"23","author":"DJ Harvey","year":"2012","journal-title":"J Am Soc Mass Spectrom"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"14954","DOI":"10.1038\/ncomms14954","article-title":"Global site-specific N-glycosylation analysis of HIV envelope glycoprotein","volume":"8","author":"L Cao","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"ref59","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1073\/pnas.88.6.2189","article-title":"Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120","volume":"88","author":"TK Hart","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"ref60","doi-asserted-by":"crossref","first-page":"8954","DOI":"10.1128\/JVI.00754-11","article-title":"Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01","volume":"85","author":"Y Li","year":"2011","journal-title":"J Virol"},{"issue":"6059","key":"ref61","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"R Pejchal","year":"2011","journal-title":"Science"},{"issue":"3","key":"ref62","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/jis367","article-title":"Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials","volume":"206","author":"DC Montefiori","year":"2012","journal-title":"J Infect Dis"},{"issue":"21","key":"ref63","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1128\/JVI.01023-12","article-title":"Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family","volume":"86","author":"M Bonsignori","year":"2012","journal-title":"J Virol"},{"issue":"5","key":"ref64","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2174\/1570162X113116660059","article-title":"Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses","volume":"11","author":"J Pollara","year":"2013","journal-title":"Curr HIV Res"},{"issue":"5532","key":"ref65","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1061692","article-title":"Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design","volume":"293","author":"EO Saphire","year":"2001","journal-title":"Science"},{"issue":"4","key":"ref66","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","article-title":"A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic beta-Hairpin Structure","volume":"46","author":"JH Lee","year":"2017","journal-title":"Immunity"},{"issue":"4","key":"ref67","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nsmb.3382","article-title":"Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer","volume":"24","author":"Q Liu","year":"2017","journal-title":"Nat Struct Mol Biol"},{"issue":"22","key":"ref68","doi-asserted-by":"crossref","first-page":"10134","DOI":"10.1073\/pnas.88.22.10134","article-title":"A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals","volume":"88","author":"DR Burton","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"ref69","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1128\/JVI.67.7.3978-3988.1993","article-title":"Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding","volume":"67","author":"M Thali","year":"1993","journal-title":"J Virol"},{"issue":"5950","key":"ref70","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"issue":"2","key":"ref71","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","article-title":"Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1","volume":"70","author":"A Trkola","year":"1996","journal-title":"J Virol"},{"issue":"7","key":"ref72","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nsmb.2627","article-title":"Antibodies expose multiple weaknesses in the glycan shield of HIV","volume":"20","author":"M Crispin","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"7","key":"ref73","doi-asserted-by":"crossref","first-page":"e70859","DOI":"10.1371\/journal.pone.0070859","article-title":"Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2","volume":"8","author":"LM Mayr","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"ref74","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1128\/JVI.03153-13","article-title":"Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV","volume":"88","author":"B Spurrier","year":"2014","journal-title":"J Virol"},{"issue":"15","key":"ref75","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1128\/JVI.00754-15","article-title":"The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel","volume":"89","author":"R Pan","year":"2015","journal-title":"J Virol"},{"issue":"2","key":"ref76","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.virol.2012.02.003","article-title":"Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals","volume":"427","author":"MK Gorny","year":"2012","journal-title":"Virology"},{"issue":"12","key":"ref77","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1128\/JVI.00205-06","article-title":"Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity","volume":"80","author":"RL Stanfield","year":"2006","journal-title":"J Virol"},{"issue":"8","key":"ref78","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nsmb.1861","article-title":"Conserved structural elements in the V3 crown of HIV-1 gp120","volume":"17","author":"X Jiang","year":"2010","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"ref79","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1128\/JVI.78.5.2394-2404.2004","article-title":"The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope","volume":"78","author":"MK Gorny","year":"2004","journal-title":"J Virol"},{"issue":"12","key":"ref80","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/nsmb.2711","article-title":"Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy","volume":"20","author":"A Bartesaghi","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"14","key":"ref81","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1128\/JVI.76.14.7293-7305.2002","article-title":"The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120","volume":"76","author":"RW Sanders","year":"2002","journal-title":"J Virol"},{"issue":"7","key":"ref82","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nsmb.2600","article-title":"Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16","volume":"20","author":"M Pancera","year":"2013","journal-title":"Nat Struct Mol Biol"},{"issue":"14","key":"ref83","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1021\/ac500876p","article-title":"Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy","volume":"86","author":"W Yang","year":"2014","journal-title":"Anal Chem"},{"issue":"5","key":"ref84","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cell.2010.04.012","article-title":"Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints","volume":"141","author":"DF Zielinska","year":"2010","journal-title":"Cell"},{"issue":"6","key":"ref85","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1021\/acs.jproteome.5b00175","article-title":"Low Abundant N-linked Glycosylation in Hen Egg White Lysozyme Is Localized at Nonconsensus Sites","volume":"14","author":"A Asperger","year":"2015","journal-title":"J Proteome Res"},{"issue":"15","key":"ref86","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"T Vesikari","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"ref87","doi-asserted-by":"crossref","first-page":"e0004423","DOI":"10.1371\/journal.pntd.0004423","article-title":"Phase 1\/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001\/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy","volume":"10","author":"JW Bennett","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"ref88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/14760584.2016.1213632","article-title":"Adjuvant system AS01: helping to overcome the challenges of modern vaccines","volume":"16","author":"AM Didierlaurent","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"20","key":"ref89","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","article-title":"Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice","volume":"30","author":"N Dendouga","year":"2012","journal-title":"Vaccine"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"P Vandepapeliere","year":"2008","journal-title":"Vaccine"},{"issue":"6","key":"ref91","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1517\/17425247.2016.1151871","article-title":"Liposomal adjuvants for human vaccines","volume":"13","author":"CR Alving","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"6","key":"ref92","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/COH.0000000000000315","article-title":"Adjuvants for HIV vaccines","volume":"11","author":"M Rao","year":"2016","journal-title":"Curr Opin HIV AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0194266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T09:16:44Z","timestamp":1604222204000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0194266"}},"subtitle":[],"editor":[{"given":"Aftab A.","family":"Ansari","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":92,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0194266","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2018,4,26]]}}}